 | Up a level |
2020
Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, F., Metzner, B., Staiger, A. M., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G. and Schmitz, N. (2020). 10-year follow-up of the R-MegaCHOEP trial: conditional survival analysis reveals 1-year progression-free survival as crucial prognostic factor for long-term outcome in young high-risk patients with aggressive B-cell lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 64 - 65. BASEL: KARGER. ISSN 2296-5262
Thurner, L., Held, G., Poeschel, V, Berdel, C., Ott, G., Schmidt, C., Viardot, A., Engel-Riedel, W., Borchmann, P., Shpilberg, O., Witzens-Harig, M., Frickhofen, N., Nickelsen, M., Griesinger, F., Krammer-Steiner, B., Neubauer, A., Federico, M., Brown, de Nully P., Stilgenbauer, S., Murawski, N., Altmann, B., Truemper, L., Schmidberger, H., Ruebe, C., Fleckenstein, J., Schmitz, N., Loeffler, M. and Ziepert, M. (2020). Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: a subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). Oncol. Res. Treat., 43 (SUPPL 4). S. 61 - 62. BASEL: KARGER. ISSN 2296-5262